CY1123477T1 - Παραγωγα βενζοξαζινονης για την αγωγη δερματικων νοσων - Google Patents

Παραγωγα βενζοξαζινονης για την αγωγη δερματικων νοσων

Info

Publication number
CY1123477T1
CY1123477T1 CY20201100988T CY201100988T CY1123477T1 CY 1123477 T1 CY1123477 T1 CY 1123477T1 CY 20201100988 T CY20201100988 T CY 20201100988T CY 201100988 T CY201100988 T CY 201100988T CY 1123477 T1 CY1123477 T1 CY 1123477T1
Authority
CY
Cyprus
Prior art keywords
treatment
skin diseases
specifically
skin
benzoxazinone derivatives
Prior art date
Application number
CY20201100988T
Other languages
English (en)
Inventor
Fredrik WÅGBERG
Göran LEONARDSSON
Original Assignee
Sixera Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sixera Pharma Ab filed Critical Sixera Pharma Ab
Publication of CY1123477T1 publication Critical patent/CY1123477T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/539—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more oxygen atoms in the same ring, e.g. dioxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με μεθόδους και συνθέσεις για την αναστολή της δράσης πρωτεασών του δέρματος, ειδικά των καλλικρεΐνης 7 ανθρώπου (KLK7), καλλικρεΐνης 5 ανθρώπου (KLK5) και καλλικρεΐνης 14 ανθρώπου (KLK14). Περισσότερο συγκεκριμένα, η εφεύρεση σχετίζεται με τη χρήση υποκατεστημένων 3,1-βενζοξαζιν-4-ονών που είναι επιλεκτικοί αναστολείς of καλλικρεΐνες του δέρματος ανθρώπου για την αγωγή δερματικών νόσων, περισσότερο συγκεκριμένα για την αγωγή φλεγμονωδών δερματικών νόσων, ειδικά συνδρόμου Netherton.
CY20201100988T 2014-01-23 2020-10-20 Παραγωγα βενζοξαζινονης για την αγωγη δερματικων νοσων CY1123477T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1430003 2014-01-23
PCT/SE2015/050062 WO2015112081A1 (en) 2014-01-23 2015-01-22 Benzoxazinone derivatives for treatment of skin diseases

Publications (1)

Publication Number Publication Date
CY1123477T1 true CY1123477T1 (el) 2022-03-24

Family

ID=53681747

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100988T CY1123477T1 (el) 2014-01-23 2020-10-20 Παραγωγα βενζοξαζινονης για την αγωγη δερματικων νοσων

Country Status (17)

Country Link
US (2) US9695194B2 (el)
EP (1) EP3097085B1 (el)
JP (1) JP6448651B2 (el)
CN (1) CN106132941B (el)
AU (1) AU2015209761B2 (el)
CA (1) CA2934025C (el)
CY (1) CY1123477T1 (el)
DK (1) DK3097085T3 (el)
ES (1) ES2820868T3 (el)
HR (1) HRP20201500T1 (el)
HU (1) HUE051296T2 (el)
LT (1) LT3097085T (el)
PL (1) PL3097085T3 (el)
PT (1) PT3097085T (el)
RS (1) RS60830B1 (el)
SI (1) SI3097085T1 (el)
WO (1) WO2015112081A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2934025C (en) * 2014-01-23 2022-06-07 Fredrik Wagberg Benzoxazinone derivatives for treatment of skin diseases
HUE059160T2 (hu) 2015-05-13 2022-10-28 Nihon Nohyaku Co Ltd Antranilát vegyület, annak sója, az említett vegyületet tartalmazó kertészeti gombaölõ szer, és eljárás annak alkalmazására
WO2017123401A1 (en) * 2016-01-13 2017-07-20 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
CN111050850A (zh) 2017-06-16 2020-04-21 阿兹特拉公司 用于用表达lekti的重组微生物治疗内瑟顿综合征的组合物和方法
GB201809378D0 (en) 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds
JP2022551583A (ja) * 2019-10-01 2022-12-12 モレキュラー スキン セラピューティクス，インコーポレイティド Ｋｌｋ５／７デュアル阻害剤としてのベンゾキサジノン化合物
BR102020009679A2 (pt) 2020-05-14 2021-11-23 Fundação Universidade Federal Do Abc - Ufabc Anticorpos recombinantes humanos para inibição da calicreína tecidual humana 7 (klk7) e uso em doenças relacionadas ao processo de descamação da pele
CN117396188A (zh) 2021-06-01 2024-01-12 西可斯拉制药公司 6-乙氧基-7-甲氧基-2-(2-甲基硫基苯基)-3,1-苯并噁嗪-4-酮的水包油乳液

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB115399A (en) * 1917-03-28 1918-04-29 Reginald Guley Lewis Improved Delivery mechanism for Coin-freed Apparatus and the like.
GB1153994A (en) * 1965-07-21 1969-06-04 Aspro Nicholas Ltd Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them
WO1999048878A1 (en) * 1998-03-24 1999-09-30 Novo Nordisk A/S Heterocyclic compounds regulating clotting
ES2341545T3 (es) * 2003-06-06 2010-06-22 Arexis Ab Uso de compuestos heterociclicos condensados como inhibidores de scce para el tratamiento de enfermedades de la piel.
TWI419884B (zh) 2010-06-24 2013-12-21 Univ Chang Gung 苯并雜氧嗪酮衍生物，其製備方法以及包含有此等衍生物的藥學組成物
CA2934025C (en) * 2014-01-23 2022-06-07 Fredrik Wagberg Benzoxazinone derivatives for treatment of skin diseases

Also Published As

Publication number Publication date
CN106132941B (zh) 2018-04-06
CA2934025A1 (en) 2015-07-30
SI3097085T1 (sl) 2020-11-30
WO2015112081A1 (en) 2015-07-30
US20170002021A1 (en) 2017-01-05
PT3097085T (pt) 2020-10-08
AU2015209761B2 (en) 2018-11-29
CN106132941A (zh) 2016-11-16
US10072024B2 (en) 2018-09-11
RS60830B1 (sr) 2020-10-30
US20170267692A1 (en) 2017-09-21
PL3097085T3 (pl) 2021-01-11
CA2934025C (en) 2022-06-07
ES2820868T3 (es) 2021-04-22
HRP20201500T1 (hr) 2020-12-25
JP6448651B2 (ja) 2019-01-09
US9695194B2 (en) 2017-07-04
JP2017503798A (ja) 2017-02-02
EP3097085A1 (en) 2016-11-30
DK3097085T3 (da) 2020-10-26
EP3097085A4 (en) 2017-08-09
HUE051296T2 (hu) 2021-03-01
EP3097085B1 (en) 2020-07-29
LT3097085T (lt) 2020-10-12
AU2015209761A1 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
CY1123477T1 (el) Παραγωγα βενζοξαζινονης για την αγωγη δερματικων νοσων
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1125436T1 (el) Αναστολεις dna-pk
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1123475T1 (el) Αναστολεις της ειδικης για λυσινη απομεθυλασης-1
CY1120969T1 (el) Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης
CY1123663T1 (el) Πυριμιδινονες ως αναστολεις τελεστη χια
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
CY1120862T1 (el) Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων
EA201591764A1 (ru) Варианты тканевого ингибитора металлопротеиназ третьего типа (timp-3), композиции и способы
CY1120517T1 (el) Διαρυλικες ενωσεις χρησιμες για την αγωγη ανθρωπινων νοσων στην ογκολογια, νευρολογια και ανοσολογια
CL2017002727A1 (es) Composiciones de ácido obeticólico y métodos de uso
CY1123906T1 (el) Αναστολεις απομεθυλασης ιστονης
BR112018005779A2 (pt) repressores de htt e usos dos mesmos
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
EA201790085A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
DK3294345T3 (da) Tpp1-formuleringer og fremgangsmåder til behandling af cln2-sygdom
CY1123707T1 (el) Νεοι αναστολεις καλλικρεϊνης 7